Introduction:
Oxford Biomedica, a leading gene and cell therapy company, has announced its acquisition of ABL Europe, a contract manufacturing organization (CMO) specializing in providing gene therapy development and manufacturing services. This acquisition will enhance Oxford Biomedica’s capabilities in manufacturing and developing gene therapies, positioning the company for further growth in the biotechnology industry.
- Oxford Biomedica has acquired ABL Europe, a contract manufacturing organization (CMO).
- ABL Europe specializes in manufacturing and developing gene therapies.
- The acquisition will enhance Oxford Biomedica’s capabilities in gene therapy development and manufacturing.
- It will position Oxford Biomedica for further growth in the biotechnology industry.
- Oxford Biomedica is a leading gene and cell therapy company.
Conclusion:
The acquisition of ABL Europe by Oxford Biomedica is a strategic move to strengthen the company’s position in the gene therapy market. This acquisition will enhance Oxford Biomedica’s capabilities in manufacturing and developing gene therapies, allowing them to meet the growing demand for innovative therapies in the biotechnology industry. It also highlights the company’s commitment to expanding its presence in the field of gene and cell therapy.
